Viatris Investor Event Summary Company Overview - **Company**: Viatris (NasdaqGS: VTRS) - **Date**: March 19, 2026 - **Key Leadership**: CEO Scott Smith, CFO Doretta Mistras, Chief R&D Officer Philippe Martin, Chief Commercial Officer Corinne Le Goff, Chief Strategy Officer Hemanth J. Varghese Core Business Segments - Viatris operates three main business segments: - **Global Generics**: A strong generics powerhouse - **Established Brands**: Includes iconic brands like Lipitor, Norvasc, Celebrex, Xanax, and Viagra - **Innovative Medicines**: A growing segment focusing on new drug development [6][5][4] Financial Performance and Projections - **2026 Revenue**: Expected to generate approximately $14.7 billion - **Adjusted EBITDA**: Projected at $4.3 billion - **EPS**: Anticipated at $2.40 per share - **Free Cash Flow**: Expected to be around $2.2 billion - **Long-term Targets (by 2030)**: - Total revenue growth: 5%-6% - Adjusted EBITDA growth: 7%-8% - Adjusted EPS growth: 9%-10% - Annual free cash flow: More than $3 billion [6][10][9] Strategic Initiatives - Focus on: - Driving base business growth - Fueling innovative portfolio development - Modernizing for sustainable growth - Plans to generate at least $11 billion in cash by 2030, balancing shareholder returns and business development [7][8][9] R&D and Pipeline Development - R&D focuses on three areas: - **Generic Medicines**: Core and complex generics - **Value-Added Medicines**: Established brands and 505(b)(2) applications - **Innovative Portfolio**: Emerging assets like Selatogrel and Cenerimod [15][16][22] Key Pipeline Assets - **Selatogrel**: A P2Y12 inhibitor for self-administered emergency treatment of recurrent myocardial infarction (MI). Expected to initiate a global registration study (SOS-MI) [26][27][30]. - **Cenerimod**: An oral S1P1 receptor modulator for systemic lupus erythematosus (SLE) and lupus nephritis. A pivotal program (OPUS) is underway with results anticipated in the first half of 2027 [31][32][36]. Commercial Strategy - Viatris has a robust commercial platform with a sales force of approximately 8,500 people, targeting growth across 165 countries [50][51]. - **Growth Drivers**: - **Europe**: Continued growth from promoted brands and generics leadership - **North America**: Leadership in complex generics and expansion of promoted brands - **Emerging Markets**: Focus on established brands leveraging physician trust [52][53][54] Upcoming Product Launches - **Fast-Acting Meloxicam**: A non-opioid option for acute pain, with peak net sales potential of up to $500 million [60][61]. - **Low-Dose Estrogen Contraceptive Patch**: Expected peak net sales of $180 million or higher, targeting young women [62][63]. - **Cenerimod and Selatogrel**: Anticipated global launches with blockbuster potential, with Cenerimod projected to exceed $1 billion in peak sales [65][68]. Conclusion - Viatris is positioned for durable growth through a diversified portfolio of generics, established brands, and innovative medicines. The company is focused on executing its strategic initiatives and leveraging its strong R&D capabilities to drive future success [69][70].

Core Viewpoint - Viatris forecasts 2026 profit below analysts' expectations due to operational disruptions from a fire at its manufacturing facility in Nashik, India [1] Financial Performance - Viatris expects adjusted per-share profit for 2026 to be between $2.33 and $2.47, compared to analysts' average estimate of $2.49 [1] - The company anticipates annual revenue to be between $14.45 billion and $14.95 billion, while analysts estimate $14.35 billion [1] - Total revenue for the fourth quarter was $3.70 billion, reflecting a 5% increase year-over-year [1] - Revenue from the branded drugs unit, which constitutes the majority of total revenue, rose by 8% during the fourth quarter [1] - The company posted an adjusted profit of 57 cents per share for the quarter ended December 31, exceeding the estimate of 53 cents [1] Operational Challenges - A fire at the Nashik facility has led to a temporary shutdown, with operations expected to resume in April [1] - The manufacturing operations in India are already under strain due to a U.S. FDA restriction on imports from one of its facilities following federal requirement violations [1] Restructuring Plans - Viatris plans to cut up to 10% of its global workforce as part of a multi-year restructuring plan [1] - This restructuring is expected to generate savings of $600 million to $700 million once fully implemented, with total pre-tax charges estimated between $700 million and $850 million [1]

Core Insights - Viatris is viewed as three distinct businesses: a global generics footprint, established products from the Upjohn acquisition, and a growing innovative segment [2] Group 1 - The global generics business includes products from Mylan and features iconic brands such as Lipitor, Norvasc, Xanax, Viagra, and Celebrex [2] - The company faced self-inflicted challenges earlier in the year, particularly with the Indore situation [3]

Summary of Viatris Conference Call Company Overview - **Company**: Viatris - **Business Segments**: - Global generics footprint (originating from Mylan) - Established products (notable brands include Lipitor, Norvasc, Xanax, Viagra, Celebrex from Upjohn acquisition) - Growing innovative segment [2][3] Core Points and Arguments - **Strategic Review**: Viatris is undergoing an enterprise-wide strategic review to assess its structure and cost efficiency, aiming for sustainable revenue and earnings growth beyond 2026 [4][20] - **Financial Performance**: - The company has returned over $1 billion to shareholders through dividends and share repurchases this year [3] - Anticipates approximately $500 million in new revenues annually from the base business, with a net growth of around $200 million after accounting for losses and price declines [8] - Internal expectations for revenue growth are higher than market estimates, with a goal to achieve continuous earnings growth over the next three to five years [7][26] - **Operating Leverage**: The company aims to improve operating leverage, targeting a growth profile shift from 1% to 3-5% [9][10] Pipeline and Product Development - **Innovative Assets**: Viatris is focusing on developing innovative products, including fast-acting meloxicam, which shows a faster onset of action compared to competitors [38][39] - **CNS Assets in Japan**: The acquisition of Aculys added CNS assets to Viatris' portfolio, with a strategic focus on growing revenues in the challenging Japanese market [32][34] - **Upcoming Launches**: The company is preparing for the launch of several products, including meloxicam and antiplatelet drugs, with significant market potential [46][63] Market Dynamics and Challenges - **External Challenges**: The company has faced external challenges such as tariffs, policy changes, and FDA regulations, which have impacted operations [2][3] - **Cost Structure Review**: Viatris is reviewing its cost structure post-merger and divestitures, aiming for significant cost savings while ensuring that these savings are sustainable [20][21] Investment and Capital Allocation - **Capital Deployment**: Viatris generates approximately $2 billion in free cash flow annually, with plans to allocate capital evenly between shareholder returns and business development [28][29] - **Focus on High-Margin Assets**: The company is looking to acquire high-margin, revenue-generating assets, particularly in the U.S. and Japan [35] Other Important Insights - **Market Positioning**: Viatris is positioning its innovative products as differentiated solutions in the market, with a focus on addressing unmet medical needs [39][63] - **Long-Term Vision**: The management emphasizes a long-term vision for growth, with a commitment to maintaining a strong base business while investing in innovation [6][26] This summary encapsulates the key points discussed during the Viatris conference call, highlighting the company's strategic direction, financial performance, product pipeline, and market challenges.

Summary of Dogwood Therapeutics (DWTX) FY Conference Call Company Overview - **Company Name**: Dogwood Therapeutics - **Industry**: Biotechnology - **Focus**: Development of novel non-opioid pain treatments targeting the NAV1.7 sodium channel for chronic pain management, particularly in cancer-related pain and chemotherapy-induced neuropathic pain [1][2][3] Core Product: Halneuron® - **Description**: Halneuron® is a NAV1.7 inhibitor, an injectable therapy aimed at reducing pain associated with cancer and chemotherapy-induced neuropathy [1][5] - **Clinical Stage**: Currently in phase 2b study [1] - **Target Patient Group**: Patients experiencing moderate to severe neuropathic pain post-chemotherapy, with about 70% of chemotherapy patients experiencing neuropathy [2][10] Clinical Data and Results - **Unmet Medical Need**: High demand for effective treatments for cancer-related pain, with millions of patients suffering globally [10] - **Study Results**: - 51% of patients treated with Halneuron® showed a 30% reduction in pain, and a 50% reduction in opioid use [11] - Placebo response rate was 35%, indicating Halneuron®'s effectiveness [11] - Durable effect observed, with patients experiencing pain relief for an average of 58 days post-treatment compared to one week for placebo [12] - **Current Phase 2b Study**: - 200 patients, assessing Halneuron® administered once daily over two weeks [14] - Primary endpoint assessed 30 days after the first dose [14] - Interim results expected by December 2025, with final results projected for mid-2026 [18][19] Regulatory Strategy - **FDA Interaction**: The company has established a good relationship with the FDA, aiming for a collaborative approach to drug approval [24] - **Fast-Track Designation**: Halneuron® has received fast-track review designation from the FDA due to its novel approach and high unmet medical need [15] Intellectual Property (IP) and Commercial Strategy - **Current IP**: Based on the unique process of collecting tetrodotoxin from pufferfish, with plans to file new IP for a synthetic formulation [29] - **Commercialization Strategy**: The company is open to partnerships but prioritizes data-driven decisions for maximizing shareholder value [30][31] Financial Position - **Cash Position**: Approximately $13.5 million on hand, sufficient to fund operations through Q1 of the following year [32] - **Burn Rate**: Low operational costs due to a small team of about 12-13 employees [32] Future Outlook - **Next Steps**: If phase 2b is successful, the company plans to initiate a phase 3 program in early 2027 and explore broader cancer-related pain studies [25][26] - **Potential Market**: With 20 million new cancer cases annually, the commercial opportunity for Halneuron® is significant [16] Additional Insights - **Team Experience**: The management team has a strong background in pain drug development, having successfully brought multiple pain medications to market [4][30] - **Synthetic Formulation**: Development of a synthetic version of tetrodotoxin is expected to improve yield, reduce costs, and enhance regulatory acceptance [21]

Summary of Dogwood Therapeutics (DWTX) Conference Call Company Overview - **Company Name**: Dogwood Therapeutics - **Ticker**: DWTX - **Industry**: Biotechnology, specifically focused on pain management - **Product**: Helmuron, a non-opioid Nav 1.7 specific channel inhibitor for treating chronic and acute pain [3][4] Core Points and Arguments Product Development - Helmuron is designed to treat chemotherapy-induced neuropathic pain (CINP) and has received fast track designation from the FDA, indicating a potential for breakthrough designation due to unmet medical needs [6][10] - The drug has shown statistically significant pain reduction in phase two studies for both CINP and general cancer pain, with a duration of response lasting upwards of two months [8][33] - Helmuron has demonstrated safety in over 700 patients, with no evidence of addiction or tolerance buildup, which are common issues with opioids [9][8] Market Opportunity - Approximately 70% of chemotherapy patients experience neuropathic pain, with 30% continuing to suffer from chronic pain six months post-treatment [19][20] - The number of patients suffering from CINP is expected to rise from 3 million to 4.5 million by 2040 due to increasing cancer diagnoses and longer patient lifespans [20] - There is a significant commercial opportunity as there are currently no approved treatments for CINP, leading many patients to rely on opioids [21][19] Intellectual Property and Competitive Advantage - Dogwood Therapeutics acquired Pharmagisix Holdings, which includes the Helmuron program, and plans to expand its intellectual property protection with a fully synthetic version of tetrodotoxin, the active ingredient in Helmuron [10][45] - The synthetic process will reset the patent clock by 20 years, providing a competitive edge in the market [45] Financial Position and Future Plans - The company has $17.5 million in capital and is burning approximately $5 million per year, allowing it to fund operations until the end of Q1 2026 [57][59] - An interim analysis of the ongoing phase 2b trial is expected in Q4 2025, with final data due in mid-2026 [42][60] - The company is exploring options for additional funding or partnerships to support the completion of clinical trials [61] Other Important Information - The team at Dogwood Therapeutics has extensive experience in drug development, having previously launched well-known drugs such as Zoloft, Viagra, and Lipitor [4] - The company is also developing two antiviral programs targeting fibromyalgia and long COVID, which are ready to progress into phase three trials [47][48] - The low float of shares and significant trading volume on positive news indicates a volatile but potentially rewarding investment opportunity [13][64] Conclusion Dogwood Therapeutics is positioned to address a significant unmet medical need in pain management with its innovative product Helmuron. The company has a strong team, promising clinical data, and a clear path forward for development and commercialization, making it an attractive opportunity for investors in the biotechnology sector [63][64]